Asthma Antiviral Nasal Spray Secures Clinical Trial Funding
A new Phase Ib clinical trial will evaluate whether a once-weekly dry powder nasal spray called INNA-051 can prime innate immune defenses and prevent viral complications in adult asthma patients, according to developer ENA Respiratory. The trial is backed by AUD $2.98 million in funding awarded through Biointelect Venturer, utilizing support from the Australian Government’s … Read more